• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Sunday, May 28, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Dr. Ekta Khurana receives grant to study prostate cancer evolution

Bioengineer by Bioengineer
March 22, 2023
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Dr. Ekta Khurana, an associate professor of physiology and biophysics at Weill Cornell Medicine, has received a 3-year, $1.2 million grant from the United States Department of Defense to investigate how prostate cancer cells evolve to become resistant to hormone-blocking therapy. This work will contribute to further understanding prostate cancer and the development of effective targeted therapies for the disease.  

Dr. Ekta Khurana Receives Grant to Study Prostate Cancer Evolution

Credit: Weill Cornell Medicine

Dr. Ekta Khurana, an associate professor of physiology and biophysics at Weill Cornell Medicine, has received a 3-year, $1.2 million grant from the United States Department of Defense to investigate how prostate cancer cells evolve to become resistant to hormone-blocking therapy. This work will contribute to further understanding prostate cancer and the development of effective targeted therapies for the disease.  

Prostate cancer growth is dependent on androgens – male hormones such as testosterone ­– binding to androgen receptors inside cancer cells. Because of this relationship, prostate cancer is commonly treated with castration or hormone therapy which disrupts this binding. In 2022, Dr. Khurana and colleagues from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center published a paper in Science that identified four subtypes of a lethal stage of prostate cancer called castration-resistant prostate cancer (CRPC). Three of these subtypes can grow independently of androgen receptors, rendering androgen-based therapies ineffective.

“Currently, patients who develop these subtypes of prostate cancer have no real targeted therapy,” said Dr. Khurana, who is also co-leader of the Cancer Genetics and Epigenetics Program at the Meyer Cancer Center and a WorldQuant Foundation Research Scholar. “This grant will enable us to identify the subtypes earlier in patients and identify new drugs that could be used to treat them to improve clinical outcomes.”

Patients with the stem cell-like subtype of CRPC (CRPC-SCL) are referred to as “double-negative” or “androgen-indifferent” and often suffer from worsening symptoms and lower likelihood of improvement from hormone-based treatment. Furthermore, it is difficult to distinguish between these tumors and tumors that are androgen dependent. This resemblance also poses a challenge to clinicians when deciding whether androgen-based therapies will be effective for patients.

Dr. Khurana and her lab team will investigate the biology of how prostate cancer evolves to be castration resistant. The overarching goals of this work will be to reduce death from prostate cancer and develop treatments that improve clinical outcomes for patients with this subtype of prostate cancer.

Specifically, the team will develop non-invasive methods to identify CRPC-SCL in a patient using tumor DNA in the blood, enabling clinicians to predict whether androgen receptor therapy will work for that patient. They will also further study the effects of drugs that might inhibit CRPC-SCL tumor growth. Finally, the group will analyze the genetics of CRPC-SCL to reveal any variants or alterations that drive its evolution.

“This work is really critical, and we are very happy we can continue to improve outcomes in patients that exhibit the prostate cancer subtype we identified,” shared Dr. Khurana. “While this grant helps us research prostate cancer specifically, I am also excited that the innovative techniques we are developing can be generalized to other cancers like breast or lung cancers to identify new subtypes and the emergence of treatment resistance.”



Share12Tweet8Share2ShareShareShare2

Related Posts

Chen-1

Protein-based nano-‘computer’ evolves in ability to influence cell behavior

May 26, 2023
Dr. Manel Esteller, Director of the Josep Carreras Institute and winner of the Admirables 2023 award for his career in biomedical research. Photo by Sonia Troncoso, Diario Médico

Dr. Manel Esteller receives the Admirables Award in Biomedical Research

May 26, 2023

Plants remove cancer causing toxins from air

May 26, 2023

ASCO23: ‘Safety & efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid & CNS tumors’

May 25, 2023

POPULAR NEWS

  • the University of Haifa

    Groundbreaking study uncovers first evidence of long-term directionality in the origination of human mutation, fundamentally challenging Neo-Darwinism

    115 shares
    Share 46 Tweet 29
  • How life and geology worked together to forge Earth’s nutrient rich crust

    35 shares
    Share 14 Tweet 9
  • Element creation in the lab deepens understanding of surface explosions on neutron stars

    34 shares
    Share 14 Tweet 9
  • The case for engineering our food

    73 shares
    Share 29 Tweet 18

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Study finds distinct patterns of pre-existing brain health characteristics in stroke patients

New moms and dads left unprepared for parenthood by government health ‘failures’, report warns

Absolute vs. relative efficiency: How efficient are blue LEDs, actually?

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 50 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In